FDA Approval of LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in PFIC
Congratulations to the Mirum Pharmaceuticals team! Yesterday they received FDA approval for LIVMARLI as a treatment for cholestatic pruritus associated with PFIC. We are so excited for PFIC patients in the US to have another tool in their toolbox to fight back against the terrible itch of pruritus. A big thank you to the Mirum team for their hard work & vision and to all the clinical trial participants who made this day possible!